Eli Lilly and Company or Travere Therapeutics, Inc.: Who Invests More in Innovation?

Eli Lilly vs. Travere: A Decade of R&D Investment

__timestampEli Lilly and CompanyTravere Therapeutics, Inc.
Wednesday, January 1, 2014473360000047795223
Thursday, January 1, 2015479640000050426000
Friday, January 1, 2016524390000070853000
Sunday, January 1, 2017528180000078168000
Monday, January 1, 20185051200000123757000
Tuesday, January 1, 20195595000000140963000
Wednesday, January 1, 20206085700000131773000
Friday, January 1, 20217025900000210328000
Saturday, January 1, 20227190800000235780000
Sunday, January 1, 20239313400000244990000
Monday, January 1, 202414271000000
Loading chart...

Unleashing insights

Innovation Investment: A Tale of Two Companies

In the competitive world of pharmaceuticals, innovation is the lifeblood of progress. Eli Lilly and Company and Travere Therapeutics, Inc. are two key players in this arena, each with a distinct approach to research and development (R&D) investment. Over the past decade, Eli Lilly has consistently outpaced Travere Therapeutics in R&D spending, with a staggering 6,900% more investment in 2023 alone. This trend highlights Eli Lilly's commitment to innovation, as their R&D expenses have grown by nearly 97% from 2014 to 2023. In contrast, Travere Therapeutics has shown a more modest increase of approximately 413% over the same period. This disparity underscores the different scales and strategies of these companies, with Eli Lilly leveraging its resources to maintain a competitive edge in the pharmaceutical industry.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025